» Articles » PMID: 17988987

Uneventful Cesarean Delivery with Administration of Factor XI Concentrate in a Patient with Severe Factor XI Deficiency

Overview
Journal Int J Hematol
Specialty Hematology
Date 2007 Nov 9
PMID 17988987
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Factor XI (FXI) is a procoagulant factor and antifibrinolytic agent, and its absence causes a bleeding tendency. FXI deficiency is autosomal in inheritance, with severe FXI deficiency in homozygotes and partial deficiency in heterozygotes. A 24-year-old primigravida with an uneventful pregnancy and no history of bleeding manifestations was admitted to our department at 38 weeks of gestation. Her blood count and serum biochemistry findings were normal except for a coagulation screen, which revealed a prolonged activated partial thromboplastin time (APTT) of 63 seconds (normal range, 24-35 seconds). The measured FXI coagulant activity of 8 IU/dL (reference range, 70-150 IU/dL) established a diagnosis of severe FXI deficiency. The breech presentation of the fetus prompted the decision for cesarean delivery under general anesthesia. We administered a single dose of FXI concentrate (15 IU/kg), which corrected the APTT to 34 seconds. The cesarean delivery was uncomplicated, and postpartum recovery of the mother and her baby was uneventful with no bleeding complications. The finding of an isolated prolonged APTT should prompt obstetricians to consider FXI deficiency. The appropriate use of factor FXI concentrate in managing obstetric patients with FXI deficiency can minimize potential bleeding complications and ensure an optimal outcome for both mother and neonate.

Citing Articles

Obstetric outcomes and acceptance of alternative therapies to blood transfusion by Jehovah's Witnesses in Japan: a single-center study.

Tanaka M, Matsuzaki S, Endo M, Kakigano A, Mimura K, Takiuchi T Int J Hematol. 2018; 108(4):432-437.

PMID: 29959745 DOI: 10.1007/s12185-018-2490-7.

References
1.
Ragni M, Sinha D, Seaman F, Lewis J, Spero J, Walsh P . Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood. 1985; 65(3):719-24. View

2.
Salomon O, Steinberg D, Tamarin I, Zivelin A, Seligsohn U . Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis. 2005; 16(1):37-41. DOI: 10.1097/00001721-200501000-00006. View

3.
Blanchette V, Sparling C, Turner C . Inherited bleeding disorders. Baillieres Clin Haematol. 1991; 4(2):291-332. DOI: 10.1016/s0950-3536(05)80162-3. View

4.
Mannucci P, Bauer K, Santagostino E, Faioni E, Barzegar S, Coppola R . Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood. 1994; 84(4):1314-9. View

5.
Saito H, Ratnoff O, Bouma B, Seligsohn U . Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med. 1985; 106(6):718-22. View